Laboratorios Serra PÃ mies, S.A. is a Spanish pharmaceutical company with over 150 years of history, specialized in the development, manufacturing, and distribution of a wide range of healthcare products. Founded in 1885 by Antonio Serra PÃ mies in Reus, Catalonia, the company provides products and services across self-care, prescription medicine, and hospital care sectors.
Core Business Activities
The company operates as an integrated pharmaceutical provider, covering the full product lifecycle from initial development to international marketing.
Manufacturing & R&D:
Serra PÃ mies produces various pharmaceutical forms, including injectables (such as midazolam and morphine), oral solids (tablets, capsules), and liquid medications.
Contract Services (CDMO):
It offers specialized services to third parties, including product development, filling, and packaging.
Logistics & Distribution:
The company maintains a centralized logistics system for shipments to pharmacies, hospitals, and large distribution chains.
Product Portfolios
Serra PÃ mies categorizes its offerings into three primary divisions:
Self-Care and Health:
Includes OTC (over-the-counter) medicines, food supplements, dermatology products (skin, hair, and nail care), and orthopedics (compression fabrics and trauma recovery gear).
Hospital Care:
Focuses on anesthetics, serums, double-distilled water, and perfusion solutions to reduce patient pain and support intensive care.
Prescription Medicine:
Develops and markets generic medications and specialized pharmaceutical specialties.
Facilities and Infrastructure
Location:
Headquartered in Reus, Spain, with additional operations in Barcelona.
Size:
Facilities span over 6,000 square meters and are equipped with state-of-the-art technology following Good Manufacturing Practices (GMP) international standards.
Workforce:
The Serra PÃ mies Group consists of approximately 300 professionals.
Recent Regulatory Status
As of late 2023, the European Medicines Agency (EMA) enforced a manufacturing suspension at Serra PÃ mies’ facility due to deficiencies uncovered during an inspection.
Scope:
The suspension affected the production and marketing of various forms including liquids, capsules, and injectables manufactured at the site.
Current Status:
While manufacturing was halted until deficiencies could be addressed, the Spanish medicines agency noted that existing batches in the market did not show compromised quality, avoiding a general product recall.
Corporate Governance
Leadership:
As of early 2024, M. Jofre Solanellas has served as Chair and CEO.
Key Brands:
Trademarks associated with the company include SERRAVET, AWPHARMA, and CBD2TAK.